

Eve Maubec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7975041/publications.pdf>

Version: 2024-02-01

102
papers

5,038
citations

101384

36
h-index

95083

68
g-index

119
all docs

119
docs citations

119
times ranked

7871
citing authors

#	ARTICLE	IF	CITATIONS
1	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. <i>Nature</i> , 2011, 480, 94-98.	13.7	466
2	Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. <i>Journal of Clinical Oncology</i> , 2011, 29, 3419-3426.	0.8	387
3	Genome-wide association study identifies three new melanoma susceptibility loci. <i>Nature Genetics</i> , 2011, 43, 1108-1113.	9.4	230
4	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Archives of Dermatology</i> , 2007, 143, 1144-50.	1.7	218
5	Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. <i>Human Molecular Genetics</i> , 2011, 20, 5012-5023.	1.4	187
6	Indolent CD8-positive Lymphoid Proliferation of the Ear. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1887-1892.	2.1	175
7	High Levels of Antibodies Against Merkel Cell Polyomavirus Identify a Subset of Patients With Merkel Cell Carcinoma With Better Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2011, 29, 1612-1619.	0.8	151
8	Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. <i>British Journal of Dermatology</i> , 2013, 169, 579-586.	1.4	141
9	Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?. <i>British Journal of Dermatology</i> , 2010, 162, 74-79.	1.4	136
10	Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3288-3295.	3.2	128
11	Distinct Merkel Cell Polyomavirus Molecular Features in Tumour and Non Tumour Specimens from Patients with Merkel Cell Carcinoma. <i>PLoS Pathogens</i> , 2010, 6, e1001076.	2.1	119
12	Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1568-1583.	3.0	108
13	Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 3051-3061.	0.8	106
14	Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines. <i>British Journal of Dermatology</i> , 2016, 174, 56-67.	1.4	102
15	Vaccination-induced cutaneous pseudolymphoma. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 623-629.	0.6	94
16	Mature Cytotoxic CD56 ^{bright} /CD16 ⁺ Natural Killer Cells Can Infiltrate Lymph Nodes Adjacent to Metastatic Melanoma. <i>Cancer Research</i> , 2014, 74, 81-92.	0.4	85
17	Early T Cell Signalling Is Reversibly Altered in PD-1 ⁺ T Lymphocytes Infiltrating Human Tumors. <i>PLoS ONE</i> , 2011, 6, e17621.	1.1	81
18	Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. <i>JAMA Dermatology</i> , 2014, 150, 535.	2.0	80

#	ARTICLE	IF	CITATIONS
19	Fetal Microchimeric Cells Participate in Tumour Angiogenesis in Melanomas Occurring during Pregnancy. <i>American Journal of Pathology</i> , 2009, 174, 630-637.	1.9	77
20	Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. <i>Anticancer Research</i> , 2005, 25, 1205-10.	0.5	73
21	Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1300-1307.	0.3	72
22	Targeted Skin Overexpression of the Mineralocorticoid Receptor in Mice Causes Epidermal Atrophy, Premature Skin Barrier Formation, Eye Abnormalities, and Alopecia. <i>American Journal of Pathology</i> , 2007, 171, 846-860.	1.9	69
23	Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapy. <i>Annals of Oncology</i> , 2016, 27, 914-919.	0.6	63
24	Management and outcome of metastatic melanoma during pregnancy. <i>British Journal of Dermatology</i> , 2010, 162, 274-281.	1.4	60
25	Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages. <i>PLoS ONE</i> , 2013, 8, e76928.	1.1	58
26	Common skin cancers in porokeratosis. <i>British Journal of Dermatology</i> , 2005, 152, 1389-1391.	1.4	57
27	Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. <i>British Journal of Dermatology</i> , 2016, 174, 813-822.	1.4	56
28	Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. <i>Journal of Oncology</i> , 2018, 2018, 1-9.	0.6	53
29	F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4mm. <i>Melanoma Research</i> , 2007, 17, 147-154.	0.6	51
30	Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature. <i>Frontiers in Medicine</i> , 2018, 5, 268.	1.2	49
31	Minocycline-Induced DRESS: Evidence for Accumulation of the Culprit Drug. <i>Dermatology</i> , 2008, 216, 200-204.	0.9	48
32	The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. <i>Experimental Dermatology</i> , 2010, 19, 100-107.	1.4	46
33	Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma. <i>Targeted Oncology</i> , 2016, 11, 59-69.	1.7	43
34	Pregnancy Promotes Melanoma Metastasis through Enhanced Lymphangiogenesis. <i>American Journal of Pathology</i> , 2011, 178, 1870-1880.	1.9	40
35	Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1781-1789.	0.3	40
36	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. <i>Nature Communications</i> , 2017, 8, 15034.	5.8	40

#	ARTICLE	IF	CITATIONS
37	Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*. <i>British Journal of Dermatology</i> , 2021, 184, 1059-1067.	1.4	39
38	Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab. <i>Archives of Dermatology</i> , 2009, 145, 329-30.	1.7	37
39	Update of the Management of Cutaneous Squamous-cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00143.	0.6	35
40	Immune recovery inflammatory folliculitis. <i>Aids</i> , 2000, 14, 617-618.	1.0	33
41	Polyomavirus-Positive Merkel Cell Carcinoma Derived from a Trichoblastoma Suggests an Epithelial Origin of this Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 976-985.	0.3	32
42	Re-Epithelialization of Pathological Cutaneous Wounds Is Improved by Local Mineralocorticoid Receptor Antagonism. <i>Journal of Investigative Dermatology</i> , 2016, 136, 2080-2089.	0.3	31
43	Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. <i>Cancers</i> , 2021, 13, 3547.	1.7	31
44	Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. <i>Cancer Gene Therapy</i> , 2003, 10, 481-490.	2.2	30
45	First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. <i>British Journal of Cancer</i> , 2016, 114, 1199-1205.	2.9	30
46	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061.	0.6	29
47	Therapy of Advanced Squamous Cell Carcinoma of the Skin. <i>Current Treatment Options in Oncology</i> , 2014, 15, 302-320.	1.3	28
48	Awareness, knowledge and attitudes towards sun protection among skin cancer-treated patients in France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 070209222700006-???	1.3	27
49	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1982-1989.	0.3	27
50	Familial melanoma: Clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1257-1264.e2.	0.6	26
51	The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. <i>British Journal of Cancer</i> , 2008, 99, 364-370.	2.9	25
52	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. <i>International Immunopharmacology</i> , 2016, 40, 466-473.	1.7	25
53	Vitamin D deficiency is associated with greater tumor size and poorer outcome in Merkel cell carcinoma patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 298-308.	1.3	24
54	Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 378-380.	1.5	23

#	ARTICLE	IF	CITATIONS
55	Characteristics of the coexistence of melanoma and renal cell carcinoma. <i>Cancer</i> , 2010, 116, 5716-5724.	2.0	22
56	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. <i>OncoImmunology</i> , 2016, 5, 1136045.	2.1	22
57	Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. <i>Immunotherapy</i> , 2019, 11, 1005-1013.	1.0	21
58	Sjögren syndrome without erythroderma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 1003-1009.e1.	0.6	19
59	Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 9534-9534.	0.8	19
60	Pathway-Based Analysis of a Melanoma Genome-Wide Association Study: Analysis of Genes Related to Tumour-Immunsuppression. <i>PLoS ONE</i> , 2011, 6, e29451.	1.1	18
61	Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa. <i>Frontiers in Medicine</i> , 2019, 6, 249.	1.2	18
62	Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN. <i>Journal of Clinical Oncology</i> , 2019, 37, 9547-9547.	0.8	18
63	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	1.7	17
64	Guidelines of the French Society of Otorhinolaryngology (SFORL), short version. Extension assessment and principles of resection in cutaneous head and neck tumors. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2014, 131, 375-383.	0.4	16
65	Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at <i>TERF1</i> and <i>AFAP1L2</i> loci on melanoma risk. <i>International Journal of Cancer</i> , 2015, 137, 1901-1909.	2.3	16
66	Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families. <i>British Journal of Dermatology</i> , 2013, 169, 594-599.	1.4	15
67	Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0133363.	1.1	14
68	Clinical Activity of Lenalidomide in Visceral Human Immunodeficiency Virus-Related Kaposi Sarcoma. <i>JAMA Dermatology</i> , 2013, 149, 1319.	2.0	13
69	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data. <i>Annals of Oncology</i> , 2021, 32, 542-551.	0.6	13
70	Mixed Nonseminomatous Germ Cell Tumor Presenting as a Subcutaneous Tissue Mass. <i>American Journal of Dermatopathology</i> , 2006, 28, 523-525.	0.3	12
71	Quality of life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020, 126, 611-618.	2.0	12
72	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 931.	1.7	12

#	ARTICLE	IF	CITATIONS
73	Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy. <i>Cancers</i> , 2021, 13, 1446.	1.7	12
74	Clinical, histopathological and prognostic features of primary cutaneous acral ⁺ Tâ€cell lymphoma and other dermal ⁺ cutaneous lymphoproliferations: results of an ⁺ EORTC</sup> Cutaneous Lymphoma Group workshop*. <i>British Journal of Dermatology</i> , 2022, 186, 887-897.	1.4	12
75	Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. <i>British Journal of Dermatology</i> , 2015, 173, 1015-1023.	1.4	11
76	BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis. , 2020, 8, e000275.		11
77	French ENT Society (SFORL) guidelines for the management of immunodeficient patients with head and neck cancer of cutaneous origin. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2014, 131, 121-129.	0.4	10
78	A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between <i>CDC42</i> and <i>SCIN</i> genetic variants. <i>International Journal of Cancer</i> , 2016, 139, 2012-2020.	2.3	8
79	Sentinel Lymph Node Biopsy or Nodal Observation in Melanoma: A Prospective Study of Patient Choices. <i>Dermatologic Surgery</i> , 2011, 37, 199-206.	0.4	7
80	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. <i>JAMA Dermatology</i> , 2019, 155, 673.	2.0	7
81	Primary cutaneous acral ⁺ Tâ€cell lymphomas relapse more frequently in younger patients. <i>British Journal of Haematology</i> , 2019, 185, 598-601.	1.2	7
82	Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. <i>ESMO Open</i> , 2021, 6, 100284.	2.0	7
83	Paraneoplastic neutrophilic leukaemoid reaction in a patient with melanoma: association between tumour volume and leucocytosis. <i>British Journal of Dermatology</i> , 2020, 183, 579-580.	1.4	4
84	Severe skin rash during vemurafenib treatment: A predictive factor of early positive response in metastatic melanoma?. <i>Journal of Clinical Oncology</i> , 2014, 32, 9092-9092.	0.8	4
85	Machine learning models to predict the response to anti-cancer therapy in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14071-e14071.	0.8	4
86	COVID-19 and skin cancer management: French nation-wide questionnaire survey from real-life practice. <i>Journal of Dermatological Treatment</i> , 2020, , 1-2.	1.1	3
87	Cetuximab as first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin: Preliminary results of a phase II multicenter study. <i>Journal of Clinical Oncology</i> , 2008, 26, 9042-9042.	0.8	3
88	CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9596-TPS9596.	0.8	3
89	The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 2243.	1.7	2
90	Sentinel node biopsy in the initial evaluation of 87 patients with Merkel cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9015-9015.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.. Journal of Clinical Oncology, 2016, 34, 9556-9556.	0.8	2
92	Epidemiological study of unknown primary melanoma patients from the French national melanoma database RIC-Mel.. Journal of Clinical Oncology, 2018, 36, e21571-e21571.	0.8	2
93	Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSÃ© Program.. Journal of Clinical Oncology, 2016, 34, TPS11620-TPS11620.	0.8	1
94	Carcinome Ã©pidermoÃ©de cutanÃ© : actualitÃ©s sur la physiopathologie et les stratÃ©gies thÃ©rapeutiques. Oncologie, 2018, 20, 33-36.	0.2	1
95	Recent Advanced in the Treatment of Advanced SCC Tumors. Cancers, 2022, 14, 550.	1.7	1
96	Lower risk of cutaneous squamous cell carcinomas induced by vemurafenib in non melanoma patients. Annals of Oncology, 2016, 27, vi391.	0.6	0
97	Effectiveness and Safety of Vemurafenib as Monotherapy in Unresectable or Metastatic Melanoma from an Academic Database: Real World Data to Strengthen Evidence for Payer. Value in Health, 2016, 19, A762-A763.	0.1	0
98	Estimation of The Cost of Metastatic Melanoma in France Using Melbase Data. Value in Health, 2017, 20, A427-A428.	0.1	0
99	Virus et cancÃ©rogenÃ©se cutanÃ©e. , 2014, , 285-289.		0
100	First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with in transit melanoma.. Journal of Clinical Oncology, 2015, 33, 2555-2555.	0.8	0
101	Role of time to switch from ipilimumab to anti-PD1 in anti-PD1 efficacy within the French national cohort, MelBase.. Journal of Clinical Oncology, 2017, 35, 9551-9551.	0.8	0
102	Micro- and macro-metastatic disease kinetics: Results from the French cohort Melbase.. Journal of Clinical Oncology, 2017, 35, 9538-9538.	0.8	0